上海私人后花园 – 爱上海419论坛-上海后花园论坛-夜上海论坛-上海龙凤419论坛

Li Wei, Political Commissar of Naval Yuncheng Ship —— Make Wan Li voyage a vivid classroom (the most beautiful revolutionary soldier in the new era)

　　Li Wei looked into the distance in front of Yuncheng ship.

　　Luan Chengshe (People’s Vision)

　　In hot summer, the sea and sky are vast. The naval Yuncheng ship has just successfully completed its combat readiness patrol mission for more than three months and returned to a military port.

　　It is the normal work of Li Wei, political commissar of the naval Yuncheng ship, to inspire the fighting spirit and will of officers and men, and to lead the warships of big countries to fight the wind and waves and brave the ocean. In recent years, Li Wei and the captain led the ship to participate in the "Marine Guardian — The 2020 "China-Pakistan maritime joint exercise and the escort mission of the 34th escort formation of the Navy have successfully completed various tasks.

　　"Hurry up and prepare for the assembly, Li Zhengwei will have a class this afternoon!" After lunch, the officers and men of Yuncheng Ship quickly arranged tableware and cleaned, for fear of missing the wonderful content of Li Wei’s lecture.

　　"The People’s Navy is loyal to the party, and the ship is not lost in Wan Li." Li Wei has always given full play to the role of the lifeline of political work and promoted the all-round progress and all-round perfection of Yuncheng ships.

　　"Ideological and political education must aim at the wishes and expectations of officers and men, so that officers and men can focus on analyzing what they are concerned about, and solve what problems they have in misunderstanding." Li Wei and a group of people from Yuncheng Ship Party Committee discussed in depth how to enhance the times and appeal of ideological and political education.

　　In recent years, Yuncheng ships often perform combat readiness tasks for a long time. Li Wei insisted that political work should be followed up wherever the ship sailed, and education should be covered, so as to make the voyage in Wan Li a vivid classroom. From Xisha Islands to Nansha Islands, from equator to Gulf of Aden … … Using flexible and diverse forms, the officers and men of the whole ship will continue to feel the glorious tradition and inspire their mission during the voyage.

　　"Can a strong enemy attack and win?" This is a question that Li Wei often asks himself. "As a grassroots political official, we must constantly improve our military quality and command quality, strive to be an expert in thinking and fighting, and perform our duties as commanders." Li Wei said.

　　On one occasion, Yuncheng Ship was carrying out a combat patrol mission in a certain sea area, and suddenly received an order from its superior: a warship of a certain country intended to rush into our military warning zone, and Yuncheng Ship immediately stepped forward as a formation command ship to command two frigates to respond.

　　The formation temporary party Committee quickly comprehensively analyzed and judged the tracking situation at each stage, looked for the law of action, and formulated countermeasures. After arriving at the designated sea area, Wan Yongfeng, the captain of Yuncheng Ship, commanded the formation ships to adjust their positions and deal with foreign troops in the face of the infringement of a certain country’s warships. Li Wei organized reconnaissance and evidence collection, shouted at a warship of a certain country, and finally successfully drove it away.

　　"Li Zhengwei studies and thinks deeply, and often has some unique insights. Every time he encounters professional and command problems, we study and decide together." Wan Yongfeng said.

　　In recent years, Yuncheng Ship Party Committee has actively promoted the activities of "three-to-three-strong, three-to-do" training and "thinking about war, researching war and serving war" for political cadres, and seriously organized political cadres to participate in theoretical study and practical training for navigation officers. Political cadres have been constantly transforming and reshaping into "war-type political cadres".

　　The officers and men of Yuncheng Ship know that Li Zhengwei has the habit of "four turns and one turn": when getting up, go to each cabin to see if there is any illness; When eating, walk around the dining tables to see if there are any people who can’t eat; Go to the beds when you sleep to see if you can’t sleep; When the wind and waves are heavy, turn to the duty positions to see if there is any serious seasickness and vomiting.

　　"Li Zhengwei can always give us the most powerful answer." Li Wei likes to chat with officers and men in his spare time. He can always use a personal experience or a short story to solve the doubts of officers and men in a grounded way.

　　Not long ago, in the questionnaire survey of officers and men’s thoughts organized by the detachment where Yuncheng Ship is located, all officers and men of Yuncheng Ship filled in "Yes" in the question "Do you have confidence in winning the battle with the ship’s party committee".

　　"Into the deep blue, to refine the sword of victory. We are always ready to break the waves and guard the sea! " Li Wei said.

Investigation on the dismantling industry of waste electrical appliances and electronics： low profits and long subsidy period

　　Data Map: Workers carefully disassemble waste household appliances and classify parts. Song Lichao

　　BEIJING, Beijing, December 9 (Qiu Yu) China has become the world’s largest producer of discarded electrical and electronic products. According to the data of the Ministry of Industry and Information Technology, at present, the annual scrap of major electrical and electronic products in China exceeds 200 million units, weighing over 5 million tons. There are more and more used mobile phones, computers and color TVs. What about the disposal of these wastes?

　　The green recycling rate of waste electrical appliances has been greatly improved.

　　While the amount of electrical and electronic scrap is increasing, the number of products that have undergone standardized scrap treatment is also increasing.

　　According to the White Paper on Recycling and Comprehensive Utilization of Waste Electrical and Electronic Products in China in 2015 issued by China Household Electrical Appliances Research Institute (hereinafter referred to as the White Paper), from 2010 to 2015, "four machines and one brain" — — The theoretical scrap of televisions, refrigerators, washing machines, air conditioners and computers increased from 58.54 million to 124 million.

　　During this period, the green recovery rate of "four machines and one brain" increased from 32.75% to 60.29%. The so-called green recovery rate refers to the ratio of the actual dismantling capacity of qualified enterprises to the theoretical scrapping capacity of the year.

　　Among all kinds of waste electrical and electronic products, the amount of disassembly of refrigerators and washing machines has increased significantly.

　　The 2016 Annual Report on the Prevention and Control of Environmental Pollution by Solid Waste in Large and Medium-sized Cities (hereinafter referred to as the Annual Report) issued by the Ministry of Environmental Protection shows that in 2015, the dismantling of TV sets decreased by 7.9% year-on-year, while the dismantling of refrigerators and washing machines increased by 110.9% and 93.9% year-on-year, respectively.

　　"In the past, the refrigerator was not easy to disassemble because the equipment level was not high. In recent years, major enterprises have begun to transform their equipment, the automation level of refrigerator disassembly has been greatly improved, and the amount of disassembly has also come up. "Chen Pingli, an insider with disassembly qualification, said that the increase in the amount of disassembly of washing machines is mainly due to the adjustment of national policies.

　　Data Map: A "green washing machine" produced from waste recycled plastics. Song Lichao

　　More than 100 enterprises are qualified for illegal dismantling.

　　A number of scrap buyers in Beijing revealed that some electrical and electronic products they bought would be sent to small workshops for disassembly.

　　"Illegal dismantling of waste electrical and electronic products still exists, and the degree of illegal dismantling of different products is different." Tian Hui, director of the Electrical Recycling Technology Research Institute of China Household Electrical Appliances Research Institute, told reporters that the number of illegal dismantling of waste TV sets has been small, and most of them have been dismantled by qualified enterprises.

　　Chen Pingli said that small workshops have no environmental protection investment and treatment measures. After dismantling, they will sell valuable parts and throw worthless things around, which may produce hazardous waste and pollute the environment.

　　Enterprises should be qualified to dismantle waste electrical and electronic products. According to the Annual Report, at present, 109 enterprises are listed in the subsidy list of the Waste Electrical and Electronic Products Disposal Fund.

　　China Quality Certification Center, as a third-party organization, conducts technical review on the dismantling qualification of enterprises. The staff of the center said that they would conduct field visits to each enterprise.

　　"Enterprises should standardize the management processes of waste electrical and electronic products, disassembly products and hazardous wastes," the staff member said, and enterprises should also have strict control measures for pollutants such as waste gas, waste water, solid waste and noise generated during disassembly.

　　Comprehensive price trend chart of recycled plastics from January 2014 to November 2016. Source: Zhuo Chuang Information

　　Falling commodity prices reduce industry profits

　　"Low profit" is a common problem faced by waste electrical and electronic dismantling enterprises.

　　"Dismantling products contain iron, copper, aluminum, plastics, etc. In recent years, commodity prices have dropped sharply, which has depressed profits," said a person in charge of a dismantling enterprise.

　　Taking recycled plastics as an example, according to Zhai Qiuping, an analyst at Zhuo Chuang Information, the price of recycled plastics has been declining all the way since 2014, with a year-on-year decline of 27.49% at the end of 2015. However, in 2016, recycled plastics began to bottom out.

　　"The dismantling of waste electrical and electronic appliances is an environmental protection industry, not a profiteering industry, so it needs state fund subsidies," said the person in charge of the above-mentioned enterprises. In addition, compared with some developed countries, there is still a certain gap in the management and technical level of dismantling enterprises in China. Only by constantly transforming equipment and improving the level of deep processing can we make a profit.

　　Tian Hui said that from the current point of view, there are great differences among 109 dismantling enterprises, and they are still developing and changing, and there are also some listed companies.

　　According to the "White Paper", in 2015, the level of capacity utilization of different enterprises was quite different. Some enterprises had a capacity utilization rate of more than 100%, while others had a capacity utilization rate of less than 20%. Some enterprises with insufficient financial strength have stopped production for a long time or even throughout the year, and some enterprises have been merged and reorganized.

　　Data Map: On April 8, 2013, electronic waste was everywhere in Guiyu Town, Shantou, Guangdong Province. China News Agency issued Hong Jianpeng photo

　　Enterprises report that the fund issuance cycle is long.

　　According to the Administrative Measures on the Collection and Use of Waste Electrical and Electronic Products Disposal Fund (hereinafter referred to as the Measures) implemented in 2012, the state subsidizes the recycling of waste electrical and electronic products.

　　In March this year, on the basis of "four machines and one brain", nine products, such as mobile phones and water heaters, were also included in the scope of fund subsidies, thus increasing the number of products that can be subsidized to 14. However, industry insiders said that at present, the state has not yet issued a policy to specify the specific subsidy amount for nine new products.

　　On the time of fund issuance, many dismantling enterprises reported that the issuance cycle was long.

　　"The fund was first issued in the first quarter, and then it was extended to two or three quarters, one year and nearly two years." Chen Pingli said that enterprises lost their "hematopoietic function" and had to borrow from banks to obtain liquidity and pay high interest.

　　He said that many companies are now limiting the amount of dismantling, otherwise they will not be able to operate normally. "Everyone is very difficult, but whoever is stronger will last longer."

　　Data map. China News Service reporter Li Bo photo

　　Expert: The fund policy needs further adjustment.

　　The issuance of fund subsidies shall follow the procedures stipulated in the Measures. After the enterprise declares, it will be audited by the provincial environmental protection department and reported to the Ministry of Environmental Protection. After verification by the Ministry of Environmental Protection, it will be submitted to the Ministry of Finance, which will finally pay the funds.

　　"Some enterprises didn’t get subsidies after one year or even nearly two years of declaration, because the time of declaration in different provinces is different, and the Ministry of Environmental Protection has to make unified publicity in batches, so enterprises that declare early need to wait for a long time." Tian Hui explained that it takes time to go through the process from the review and publicity of the Ministry of Environmental Protection to the allocation of funds by the Ministry of Finance.

　　She said that the imbalance between the amount of funds collected and the amount of subsidies is also the reason for the long distribution cycle. At present, the operation of the fund adopts the mode of "producers pay money and dismantlers get subsidies". The sales volume of "four machines and one brain" has not changed much, but the number of dismantlers has reached more than 70 million units per year. "The amount of subsidies required for dismantling is large. If all of them are distributed, the fund pool will be affected."

　　How to solve the above problems? Tian Hui said that the fund policy needs further adjustment, and the pilot work of extending producer responsibility of electrical and electronic products initiated by the Ministry of Industry and Information Technology in 2015 provided support for the adjustment.

　　It is understood that the core of the extended producer responsibility system is to encourage producers to implement product source control and green production by guiding product producers to take responsibility for recycling and resource utilization after product abandonment, so as to maximize resource utilization efficiency in the whole product life cycle.

　　"Now producers and dismantlers are two independent subjects. In the future, we hope to establish a system to link them and encourage producers to take certain responsibilities," Tian Hui said. (Some characters in the text are pseudonyms) (End)

The Ministry of Industry and Information Technology abolished and adjusted a number of mandatory standards for industrial communications.

According to the State Council’s work requirements of deepening standardization reform and streamlining mandatory standards, the Ministry of Industry and Information Technology recently carried out a comprehensive clean-up of the mandatory industry standards of industrial communication industry, and decided to abolish 150 mandatory industry standards such as davit poles and adjust 354 mandatory industry standards such as Hexamethylene to recommended industry standards. This conclusion has been deliberated and agreed by the the State Council Inter-Ministerial Joint Conference on Standardization Coordination and Promotion.

Recently, the Ministry of Industry and Information Technology issued an announcement announcing the abolition and adjustment of a number of mandatory standards for industrial communications. The announcement pointed out thatAccording to the State Council’s Work Plan for Deepening Standardization Reform and the State Council’s General Office’s Work Plan for Integrating and Streamlining Compulsory Standards, the Ministry of Industry and Information Technology has carried out a comprehensive clean-up of compulsory industry standards in industry and communications. After evaluation and item-by-item review, the Ministry of Industry and Information Technology put forward the conclusion of integration and simplification, which has been reviewed and agreed at the third plenary session of the the State Council Inter-ministerial Joint Conference on Standardization Coordination and Promotion (hereinafter referred to as the Joint Conference).

According to the requirements of the Notice of the Joint Conference Office on Printing and Distributing the Conclusions on the Integration and Simplification of Compulsory Standards (National Standards Committee Comprehensive Letter [2017] No.4), the Ministry of Industry and Information Technology decided to abolish 150 compulsory industry standards (see Annex 1 for details), including 2 in shipbuilding industry, 1 in textile industry, 43 in chemical industry, 2 in pharmaceutical equipment industry, 29 in machinery industry, 58 in light industry and civil explosion industry. It is decided to adjust 354 compulsory industry standards such as Hexamethylene to recommended industry standards (see Annex 2 for details), including 129 in chemical industry, 9 in metallurgical industry, 31 in building materials industry, 1 in rare earth industry, 4 in machinery industry, 23 in pharmaceutical equipment industry, 13 in shipbuilding industry, 67 in light industry, 42 in textile industry, 2 in packaging industry and 22 in civil explosion industry.

Annex 1: List of abolished compulsory industry standards (150 items)

Annex 2: List of mandatory industry standards converted into recommendations (354 items)

The main respiratory syncytial virus infected in winter finally has a preventive medicine.

Respiratory syncytial virus (RSV) is one of the most frequently mentioned respiratory infectious diseases or pathogens in the winter of 2023.

Last November, at the press conference organized by National Health Commission, RSV was mentioned many times. On November 13, 2023, Wang Quan, chief physician of Beijing Children’s Hospital, said, "On the whole, virus is still the most common pathogen of respiratory tract infection in children, including influenza virus, rhinovirus, adenovirus and respiratory syncytial virus." On November 26, 2023, Mi Feng, spokesperson of the National Health and Wellness Commission and deputy director of the Propaganda Department, once pointed out that "monitoring shows that recently, respiratory infectious diseases are mainly influenza. In addition, rhinovirus, mycoplasma pneumoniae, respiratory syncytial virus, adenovirus, etc. "

RSV is a negative single-stranded RNA virus belonging to the genus Pneumonia of Paramyxoviridae. It is named because it is related to respiratory tract infection and can fuse infected cells. Moreover, RSV is the pathogen of acute respiratory infection after influenza.

According to a prospective surveillance study on all-age patients with acute respiratory infection in China from 2009 to 2019, the etiology and epidemiological characteristics of about 231,000 patients were analyzed. As a whole, influenza (28.5%), RSV(16.8%) and rhinovirus (16.7%) were the most common virus pathogens. Children and the elderly are the key people infected with RSV. Among them, in children under 5 years old, the positive rate of RSV detection exceeds that of influenza and rhinovirus, and RSV has become the most common virus pathogen that causes respiratory tract infection in children.

On January 2nd, AstraZeneca and Sanofi jointly announced that the long-acting monoclonal antibody Nirsevimab/Nisevimab was officially approved for marketing in National Medical Products Administration, China, to prevent lower respiratory tract infection (LRTI) caused by RSV in newborns and infants. This also fills the gap that there is no medicine for preventing RSV infection in infants in China.

It is worth noting that nisevimab is the first and only approved preventive measure to protect infants from RSV infection in China, covering healthy full-term infants, premature infants and infants susceptible to severe RSV infection due to special health conditions. In addition, nisevimab can achieve the effect of continuous protection for 5 months with one injection, that is, a typical RSV infection season (November-April in the northern hemisphere, totaling 5-6 months).

AstraZeneca and Sanofi revealed that nisevimab is expected to be listed in China during the RSV infection season in 2024-2025. Previously, nisevi monoclonal antibody had been approved in the European Union and the United States. The listing applications submitted by nisevimab in Japan and other markets are also under review.

At present, there are two main ways to prevent RSV infection: vaccination and drug prevention. In terms of drugs to prevent infection, infants can prevent RSV infection by injecting palizumab or nisevimab, while adults have no related RSV preventive drugs at present.

Both palizumab and nisevimab are products of AstraZeneca. Among them, palizumab is the first drug approved for the prevention of RSV infection in children in the world. It was approved for marketing in the United States in 1998 and has not been approved for marketing in China yet. The population covered by this drug is small, and the EU only recommends the use of this drug for premature infants within 6 months and under 35 weeks after birth, children with bronchopulmonary dysplasia (BPD) who need treatment in the past 6 months, and children with congenital heart disease (CHD) who are over 24 months old.

Moreover, compared with only one injection of nisevizumab in an RSV epidemic season, palizumab needs to be injected once a month in the RSV epidemic season, and the drug price is high.

In terms of vaccines, in 2023, the FDA approved the listing of RSV vaccines from Pfizer and GlaxoSmithKline. Infants within 6 months can take the initiative to inoculate Pfizer bivalent RSV vaccine Abysvo at 24-36 weeks of pregnancy to prevent RSV-related lower respiratory diseases, while people over 60 years old can be inoculated with GlaxoSmithKline’s RSV vaccine Arexvy or Pfizer bivalent RSV vaccine Abysvo for prevention, and there is no relevant RSV vaccine on the market for other age groups.

At present, GlaxoSmithKline’s RSV vaccine has been approved for clinical trials in China and has reached cooperation with domestic pharmaceutical companies. On June 19th, 2023, China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that the RSV vaccine (AS01E adjuvant system) declared by GlaxoSmithKline had obtained implied permission for clinical trials and was suitable for active immunization to prevent lower respiratory diseases in adults aged 60 and above caused by RSV-A and RSV-B subtypes. On October 8, 2023, GlaxoSmithKline reached a strategic cooperation with Zhifei Bio, and Zhifei Bio won the priority agency right of RSV vaccine in mainland China.

It is worth mentioning that not long ago, the only RSV vaccine giant started a patent war. In August 2023, GlaxoSmithKline filed a patent lawsuit against Pfizer, claiming that Pfizer’s RSV vaccine Abrysvo infringed four patents of GlaxoSmithKline’s vaccine Arexvy. If GlaxoSmithKline wins the case, Pfizer will be permanently banned from selling and producing RSV vaccine in the United States in the future.

RSV is considered as the next field with a market of 10 billion dollars. Minsheng Securities Research Report shows that the overall global market size of RSV drugs (including preventive and therapeutic drugs) is expected to increase from $1.8 billion in 2020 to $12.8 billion in 2030, with a compound annual growth rate of 21.4%.

The market potential of RSV can be seen from the sales of products that have been listed. The aforementioned two RSV vaccines, Abrysvo of Pfizer and Arexvy of GlaxoSmithKline, achieved revenue of $375 million and $870 million respectively in the first quarter after being approved for marketing. Insight database shows that even palizumab, which has extremely limited coverage and short effect duration, has reached a sales peak of $1.6 billion in the past decade.

Many domestic pharmaceutical companies have also joined the development of the 10 billion blue ocean market. From the domestic research and development of RSV vaccine, many pharmaceutical companies, such as watson biological/Blue Magpie Bio, Unacon, Zhifei Bio, Clover Bio, Aidiweixin, participated in the research and development of RSV vaccine, but most of them are still in the early stage. Among them, the research and development progress of Aidiweixin is relatively fast, and its product ADV110 is in the second clinical stage; It is estimated that the phase II study will be extended from the elderly group to the infant group in 2024, aiming at protecting children aged 6 months to 5 years and the elderly over 65 years old.

According to the research of children’s RSV preventive drugs, TNM001 of Tylenol Mai Bo is in phase II/III clinical research, and RB0026 of Ruiyang Biotechnology is in phase I clinical trial. In addition to the products already on the market, the fastest research and development progress in the world is Clesrovimab of Merck, which has been in phase III clinical research.

Judging from the drugs under research for the treatment of children’s RSV infection, the domestic pharmaceutical company Aike Baifa AK0529 has submitted an application for NDA registration, and the progress is leading. AK0529 is an oral drug, which is suitable for children from birth to 24 months old. In addition, RV521 from Pfizer and EDP-938 from Enanta are under research all over the world, all of which are oral drugs, suitable for children aged from January to 36 months and 28 days to 36 months respectively. As of October 20, 2023, these two products are in phase II clinical trials.

Tencent Music’s ＂Yunwan Night If Music Has Shapes＂ concert was held in Shenzhen to warm autistic children with music.

On September 5th, 2024 Tencent Global Digital Ecology Conference was grandly opened in Shenzhen International Convention and Exhibition Center, and the concert "If Music Has Shapes" at Yunwan Night that night was even more dazzling. In this music feast full of love and warmth, Tencent Music Public Welfare, a subsidiary of Tencent Music Entertainment Group ("TME"), played a vital role.

As the co-organizer of the concert, Tencent Music Public Welfare took active actions and invited outstanding musicians such as Lian Liu and Lu Yupeng to perform on the same stage with autistic children. They used music to build a bridge of communication and care for the growth of autistic children, and also officially opened this year’s "TME Music Care Public Welfare Season". This series of music public welfare special activities, like a spring breeze, brought warmth and hope to autistic children.

At the opening of the concert, the Autistic Youth Orchestra "Aite Orchestra" and the young singer Lu Yupeng performed the song "Teenagers" hand in hand. The simple and moving performance of teenagers, like a clear spring, flows into the hearts of every audience at the scene, conveying gentle and firm strength. As a musical actor, Lu Yupeng knows the power of music. He sang the musical song Stars, which he starred in, because autistic children are often called "children of stars". He hopes that through this warm song, autistic children will feel full of love in the beautiful melody.

Autistic children are not good at expressing their feelings and thoughts in words, but they show more interest in music, painting and other fields. They communicate with the world through these art forms and show their unique inner world. At the Yunwan Night Concert, autistic children Zhou Bohan and Xiang Yixin played wonderful melodies on piano and violin, adding touching colors to singer Lian Liu’s singing. Lian Liu sang three songs with deep affection: She with the light on her pillow, There are so many people in this world, and Endless Life. Her singing is like a ray of sunshine, which shines on everyone’s heart.

Since 2017, TME has launched a special program of music care for autistic children with music as a bridge. They release caring songs, create digital albums and hold special concerts for these children. Today, this charity activity has entered its eighth year. Zhou Bohan is an autistic child who has been accompanying and caring for Tencent Music Public Welfare since 2017. In the past eight years, Tencent Music Public Welfare has accompanied more and more "Xingwa" to move forward and witness their growth and progress.

In 2023, "Yunwan Night" cooperated with Tencent Music Public Welfare Music Park, and played the movement of "being good" in technology and music. This year, Tencent Music Entertainment Group has condensed the care of autistic groups from all walks of life by cooperating with the public welfare activity IP "If Music Has Shapes". In the form of cross-border performances by well-known musicians and autistic teenagers, it has inspired a deeper and more inspiring force for goodness in music.

Cussion Pang, executive chairman of Tencent Music Entertainment Group, once said: "We hope to unite the strength of the whole music industry, all musicians and music users, and we hope to cooperate with more relevant government agencies, non-profit organizations and social caring people to build a music public welfare platform in which more musicians and users can participate."

In the future, TME will continue to explore the broader social value of music, and will try a new way to integrate music, public welfare and technology, and contribute more humanistic strength to building a new era of digital ecology. Tencent Music Entertainment Group firmly believes that music is not only an art form, but also a force to convey love and hope. Through music public welfare activities, they will bring warmth and care to autistic children and more groups in need of care, and make the world a better place.

With the efforts of TME, music is no longer just entertainment, but also a responsibility and responsibility. They interpret the power of music with actions and write a bright future with love. I believe that with the continuous efforts of Tencent Music Entertainment Group, more and more people will join the ranks of music public welfare and jointly create a better world for autistic children and other groups in need.

Revealing the company behind Remdesivir, a ＂new life-saving drug for pneumonia＂： in less than 30 years, it ranks among the TOP10 global pharmaceutical companies.

Titanium media note:Since the outbreak of new coronavirus pneumonia, pharmaceutical research has been the focus of public attention.

On January 31st, the authoritative medical journal NEJM published a paper, which introduced the diagnosis and treatment process of the first confirmed case in the United States, and mentioned that the patient’s condition was rapidly relieved after receiving experimental treatment with Remdesivir, a drug developed by Gilead Scientific Company.

Since then, Gilead has issued a statement on the drug research and development action taken against the new coronavirus in 2019, and said that it is working closely with the health authorities in China. On February 4th, Remdesivir arrived in China, and will start a clinical trial to treat Covid-19 pneumonia in China.

This series of measures made the pharmaceutical company behind Remdesivir, Gilead, attract widespread attention.

Today, after Wuhan Virus Institute publicly declared the patent of antiviral drug Remdesivir, the global CEO of Gilead Science responded to this "patent dispute" at a company meeting.

Patents are not our primary concern at present. I asked my colleagues in charge of patents. Just like other drugs of Gilead, we have applied for compounds and patents including coronavirus for Remdesivir in various regions of the world. We will not get involved in this patent issue, we will find ways to help patients, and of course we will protect our intellectual property rights in other ways, but patients come first.

Gilead’s patient-oriented pharmaceutical spirit has once again focused on the public’s vision. So, what kind of enterprise is Remdesivir’s Gilead Science Company?

Founded in 1987, Gilead Science Company is a biopharmaceutical company engaged in drug development and sales based on research. Headquartered in California, Gilead is known as the "Apple Company in Pharmaceutical Industry" for its innovative ability.

Twenty-eight products were listed in 31 years, and single-chip compound agent for AIDS treatment was listed in 2006. In 2013, Sovaldi, the first "medicine for hepatitis C", entered the first echelon of global CAR-T therapy in 2017. It took Gilead less than 30 years to become one of the TOP10 global pharmaceutical companies.

Gilead’s success comes from high R&D investment, which is based on the first bucket of gold brought by the founder.

Michael Aodan is the founder of Gilead. When the company was founded in 1987, Aodan, who was only 29 years old, was already good at capital operation. In the second year after its establishment, Aodan raised $2 million in venture capital. In 1989, Aodan received another $10 million in venture capital, from which many projects were studied.

Although Aodan received many venture investments in the early days of his business, Gilead was a drop in the bucket in the first few years. It was not until March 1991 that Gilead won the first cooperation fund of 1.3 million US dollars, and in the same year signed an agreement with a European university laboratory to obtain the right to develop a group of nucleotide compounds, so Gilead was able to start the research in the field of antiviral drugs that he had been focusing on since then.

Since then, while Gilead’s R&D investment has achieved fruitful results, funds have also been rolling in. In January 1992, Gilead went public, which provided financial support for its huge R&D investment.

After eight years of "pioneering", Gilead accumulated $167 million in assets, and the enterprise was at the dawn. Gilead continues to focus on human immunodeficiency virus (HIV)/ AIDS, liver diseases, blood/tumors, cardiovascular diseases and inflammatory/respiratory diseases.

In later years, Gilead developed a series of products to fight virus and inflammation, including AmBisome, Atripla, Cayston, Complera/Eviplera, Descovy, Emtriva and so on.

In order to devote himself to the research and development of antiviral drugs, Gilead also sold the antisense therapy studied for many years to Ionis pharma and the tumor business to OSI pharma.

Gilead has rewritten the course of treatment of major human diseases many times, including oseltamivir (Tamiflu), a well-known anti-influenza drug. It took only seven years for oseltamivir to go on the market successfully, which is rare and efficient in the history of modern new drug research and development, and has also become a classic case of structure-based drug design.

In 2016 -2018 and the first three quarters of 2019, the net profit attributable to shareholders of the parent company after deduction by Gilead Science was 93.656 billion yuan, 30.240 billion yuan, 37.439 billion yuan and 19.026 billion yuan respectively, and the R&D expenses in the same period were 35.365 billion yuan, 24.399 billion yuan, 34.440 billion yuan and 50.974 billion yuan respectively.

Up to now, Gilead’s total R&D investment is $25.02 billion, but the return is as high as $175 billion, and this is not the value of the products under research.

The solid capital base is endorsed by the high R&D expenses, and a large amount of investment in R&D has promoted the continuous growth of the company’s income, forming a virtuous circle for the long-term development of Gilead.

If Gilead’s success stems from its strategy of attaching importance to research and development, then its growth can not be separated from the merger and acquisition in the past two years.

In June 2010, Gilead acquired CGI Pharmaceuticals, a private company, with a purchase price of $120 million. This biotechnology company has a batch of very potential patented small molecule kinase inhibitors, including preclinical candidate compounds targeting spleen tyrosine kinase (Syk).

In February 2011, Gilead announced the acquisition of Calistoga Pharmaceuticals for $375 million. This is a biotechnology company in the clinical development stage. The main candidate drug is CAL-101, a highly selective inhibitor of PI3K, which is the first in the world. Later, Gilead changed its code name to GS-1101, that is, Zydelig, a listed product. In 2014, Zydelig was approved for the treatment of chronic lymphocytic leukemia and lymphoma.

In 2012, Gilead also acquired Pharmasset for $11 billion. At that time, Pharmasset Pharmaceutical Company only had 82 employees, but its greatest value was its possession of PSI-7977, a hepatitis C treatment drug, which was named Sovaldi after it went on the market. After Sovaldi was approved for marketing, HCV therapeutic drugs Harvoni and Epclusa were listed in succession. By the first quarter of 2017, the sales of these three drugs had reached 49.2 billion US dollars.

The popularity of Sovaldi, the "magic medicine for hepatitis C", has caused the market value of Gilead to skyrocket five times. Harvoni, the second-generation hepatitis C drug, ranked second in the global drug sales list in 2015 and 2016.

This also enabled Gilead to become the top 10 pharmaceutical companies in the world in July 2015, with a market value as high as 160 billion US dollars.

Since then, Gilead has successively acquired pharmaceutical companies with R&D potential such as Epitherapeutics, Kite Pharma and Cell Design Labs, further expanding its pharmaceutical field and territory.

The continuous growth of Gilead’s science is inseparable from its continuous global expansion. This pharmaceutical company entered China in 2007 and established its Shanghai headquarters in 2016.

In 2017, since the first chronic hepatitis C treatment drug Sovadi of Gillette Science was approved in China, eight drugs have been listed in China, covering hepatitis B, hepatitis C and HIV/ AIDS. The approval of hepatitis B drug Vemlidy in China achieved a 52% increase. Gilead predicted that with the penetration of the US market and the pull of the China market, Vemlidy could achieve a revenue of $1 billion in 2022.

On May 30, 2018, a new drug for the treatment of hepatitis C by Gilead’s pan-genotype was approved in China; In November 2019, four drugs from Gillette Company were included in the 2019 edition of the National Medical Insurance Catalogue.

A few days ago, the news of the recovery of the first confirmed case of Covid-19 came from the United States, and the Remdesivir developed by Gilead Science Company made it the focus of media attention. After the news that taking Remdesivir improved his condition, Gilead rose by 3% immediately after the close. Thus, for Gilead, its global layout has become an indispensable driving force for the continuous growth of the enterprise.

Although the investment in pharmaceutical research and development is high and the cycle is long, gambling can bring high returns. For Gilead, it is because of his long-term concentration and daring to take risks that he can stay ahead in this fierce and high-risk field.

(Titanium media editor Tao Tao integrated from Snowball, sohu finance)

Announcement of the State Council Customs Tariff Commission on Increasing the Tariff Rate on Some Imported Goods Originated in the United States

The State Council Customs Tariff Commission’s Report on the Application of the United StatesAnnouncement on raising the tariff rate for some imported goods
Announcement No.3 [2019] of the Tax Commission

On May 9, 2019, the U.S. government announced that from May 10, 2019, the tariff rate on 200 billion U.S. dollars of list goods imported from China will be increased from 10% to 25%. The above-mentioned measures by the United States have led to the escalation of Sino-US economic and trade frictions, which violates the consensus of China and the United States on resolving trade differences through consultation, harms the interests of both sides, and does not meet the general expectations of the international community.

According to the Foreign Trade Law of People’s Republic of China (PRC), Regulations on Import and Export Tariffs of People’s Republic of China (PRC) and other laws and regulations and the basic principles of international law, the State Council Customs Tariff Commission decided to increase the tariff rate on some imported goods originating in the United States from 0: 00 on June 1, 2019. The relevant matters are hereby announced as follows:

1. For some goods in the Announcement of the State Council Customs Tariff Commission on Imposing Tariffs on Imported Goods Originating in the United States of America of about 60 billion US dollars (Announcement No.8 of the Tax Commission [2018]), the tariff rate will be increased, and it will be implemented according to the announcement of the State Council Customs Tariff Commission on Imposing Tariffs on Some Imported Goods Originating in the United States (Announcement No.6 of the Tax Commission [2018]). That is, a tariff of 25% will be imposed on 2493 items listed in Annex 1; Impose a 20% tariff on 1078 items listed in Annex 2; A 10% tariff will be imposed on 974 items listed in Annex 3. A tariff of 5% will still be imposed on the 595 items listed in Annex 4.

2. Other matters shall be implemented in accordance with Announcement [2018] No.6 of the Tax Commission.

Annex: 1. List of goods subject to 25% tariff on the United States

　　　 2. List of goods subject to 20% tariff on the United States

　　　 3. List of goods subject to 10% tariff on the United States

　　　 4. List of goods subject to 5% tariff on the United States

The State Council Customs Tariff Commission
May 13, 2019

Sales of 58,800 models／2 models Wuling Zhengtu officially listed.

　　[car home new car listed] On March 18th, SAIC-GM-Wuling officially announced its first youth pickup truck.Wuling Zhengtu officially guides the selling price. The new car has launched two models with the selling price of 58,800 yuan and 62,800 yuan respectively.. As the opening gift of Wuling brand, this listing, (|) in order to help young people bravely embark on the struggle journey and provide warm-hearted car purchase benefits, users can order through the e-commerce 9.9 yuan, and the top 10,000 people can get exclusive benefits worth 3,500 yuan, including: 2,000 yuan gratitude replacement gift, four free maintenance times in two years (exclusive benefits ordered by Lingling State). See the table below for the detailed price of the new car:

Wuling journey guide price car make and model Price (ten thousand yuan) Aggressive type 5.88 pioneering 6.28

● New car features

Home of the car